Would carvacrol be a supporting treatment option effective in minimizing the deleterious effects of COVID-19?

Fernanda Oliveira de Carvalho, Jessica Paloma Rosa Silva, Érika Ramos Silva, Ricardo Luiz Cavalcanti de Albuquerque Júnior, Paula Santos Nunes, Adriano Antunes de Souza Araújo

Received: 3 June 2021 / Accepted: 12 October 2021 / Published online: 20 October 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
The pathophysiological process of the disease COVID-19 is mediated by innate immunity, with the presence of macrophages responsible for secreting type 1 and 6 interleukins (IL), tumor necrosis factor (TNF) leading to dilation of endothelial cells with a consequent increase in capillary permeability. The treatment of this disease has been much discussed, but the variability in the clinical picture, the difficulties for diagnosis and treatment, especially of those patients who have the most severe clinical condition of the disease. Immunization is an effective tool for controlling the spread and overload of health services, but its effectiveness involves high investments in the acquisition of inputs, development of vaccines, and logistics of storage and distribution. These factors can be obstacles for countries with lower economic, technological, and infrastructure indexes. Reflecting on these difficulties, we raised the possibility of adjuvant therapies with imminent research feasibility, as is the case with the use of carvacrol, a monoterpenic phenol whose biological properties that serve as a barrier to processes mediated by free radicals, such as irritation and inflammation, due to its antioxidant action. Many authors highlighted the activity of carvacrol as a potent suppressor of COX-2 expression minimizing the acute inflammatory process, decreasing the release of some pro-inflammatory mediators such as IL-1β, TNF-α, PGE2. Anyway, the benefits of carvacrol are numerous and the therapeutic possibilities too. With this description, the question arises: would carvacrol be a supporting treatment option, effective in minimizing the deleterious effects of Covid-19? There is still a lot to discover and research.

Keywords SARS-Cov-2 · Covid-19 · Carvacrol · Monoterpene

SARS-CoV-2 has great potential for transmission and rapid replication. Its worldwide spread has caused high mortality and morbidity, and negative impacts on the economy of some countries (Asselah et al. 2021).

The pathophysiological process of the disease COVID-19 is mediated by innate immunity. When cell changes of pathological origin are recognized, type I and III interferons associated with other inflammatory cytokines enter the transcription process (Khalaf et al. 2020). After viral infection reaches type II pneumocytes, the viral spike protein binds to SARS-CoV-2 receptor ACE-2. Soon after, the virus enters the nucleus of the ribosome, leading to the translation of
its genome + ssRNA into different protein molecules (Letko et al. 2020).

In response, type II pneumocytes initiate the process of releasing inflammatory mediators, promoting macrophages to secrete type 1 and 6 interleukins (IL) and tumor necrosis factor (TNF) leading to dilation of endothelial cells with a consequent increase in capillary permeability. With the accumulation of fluids inside the alveoli, it is possible to observe edema with increased surface tension, leading the individual to present a decline in gas exchange, with a worrying prognosis when related to the respiratory function; the most commonly described is acute respiratory distress syndrome (ARDS) (Zhao et al. 2020).

The treatment of this disease has been much discussed, but the variability in the clinical picture and the difficulties for diagnosis and treatment, especially of those patients who have the most severe clinical condition of the disease, raise discussions about auxiliary methods, which holds the progression of the pathophysiology or that optimizes the effectiveness of the treatment. Immunization is an effective tool for controlling the spread and overload of health services, but its effectiveness involves high investments in the acquisition of inputs, development of vaccines, and logistics of storage and distribution. These factors can be obstacles for countries with lower economic, technological, and infrastructure indexes. Reflecting on these difficulties, we raised the possibility of adjuvant therapies with imminent research feasibility, as is the case with the use of carvacrol, a monoterpenic phenol whose therapeutic potentials are recognized by alternative or complementary medicine from several countries in the Asian continent (such as China), in the Mediterranean (for example, Lebanon), or in South America (Lima et al. 2013; Khoury et al. 2016; Silva et al. 2018).

This volatile compound, with a distinctive odor, is found in aromatic plants and essential oils, even being the main component of the fractions of *Origanum vulgare* (oregano) and *Thymus vulgaris* (thyme) (Ipek et al. 2005; Liolios et al. 2009). Carvacrol is recognized as safe and its use in food has been approved by the European Food Safety Authority and the Food and Drugs Administration (FDA) (). It is a safe additive that increases the shelf-life of food as a flavoring agent and that acts against microorganisms (Ultee and Smid 2001). Furthermore, in 2018, Ghorani et al. (2018) published a phase 1 clinical study, which was designed to evaluate the safety and tolerance of carvacrol at high doses (1 and 2 mg/kg/day) for 1 month in healthy subjects. The effects of carvacrol in healthy subjects showed clinical safety and tolerability for this agent.

The natural antimicrobial action (Mastelic et al. 2008; Beena and Rawat 2013) is based on disturbance of the cytoplasmic membrane, disruption of electron flow, interference with active transport, inhibition of coagulation of cytoplasmic content, and enzyme activity. Its inhibitory action on the production of toxins has been proven in food (Ultee and Smid 2001), which demonstrates great potential for use in large populations.

Carvacrol has biological properties that serve as a barrier to processes mediated by free radicals, such as irritation and inflammation, due to its antioxidant action (Silva et al. 2018; Mastelic et al. 2008; Beena and Rawat 2013; Guimarães et al. 2010). Moreover, through experimental studies, it was observed that carvacrol is also responsible for hepatoprotective actions (increasing the rate of liver regeneration) (Uyanoglu et al. 2008), anti-bactericidal (Lambert et al. 2001; Mathela et al. 2010), antifungal (Pina-Vaz et al. 2004; Pete et al. 2012), antitumor (He et al. 1997), anti-elastase (Baser 2008), and anti-inflammatory and antiplatelet (Son et al. 2005), which is important to highlight, given that SARS-CoV-2 causes a state of hypercoagulability, possibly due to, among other factors, the tissue damage that is generated, stimulating platelet activation and aggregation, leading to the microthrombus formation and greater platelet consumption. Carvacrol is also related to reparative and tissue protective action (Lima et al. 2013; Guimarães et al. 2010, 2012; Landa et al. 2009).

In the last fifteen years, experimental researches testing this product have proven beneficial effects in the combat of several diseases, among which it is worth mentioning: lung injuries (Şen et al. 2014) or chronic obstructive pulmonary disease (Boskabady and Gholami 2015); cardiovascular diseases (Wei et al. 2013); cerebral edema (Zhong et al. 2013).

Many authors, such as Wagner et al. (1986), Guimarães et al. (2010), Botelho et al. (2009), Hotta et al. (2010), Landa et al. (2009), Guimarães et al. (2012), and Lima et al. (2013), highlighted, in their preclinical studies with animals, the activity of carvacrol as a potent suppressor of COX-2 expression; and therefore, its anti-inflammatory effect is certainly associated with prostaglandin inhibition, minimizing the acute inflammatory process and decreasing the release of some pro-inflammatory mediators such as IL-1β and TNF-α, as well as inhibiting NO release. In addition, a clinical trial published in 2019 showed that levels of IL-10, an anti-inflammatory cytokine, were enhanced (Lima et al. 2013; Hotta et al. 2010; Khazdair and Boskabady 2019a, b).

However, it is crucial to mention the study that was published by Reese et al. (Reese et al. 2021), which addresses the use of COX inhibitors associated with increased severity of COVID-19. In this paper, the authors performed a retrospective observational study, analyzing eight COX inhibitors and demonstrated a significant association of the use of five of eight different COX inhibitors with increased clinical severity and mortality. The other three inhibitors that did not obtain evidence of an association of increased severity of COVID-19 were those selective for COX-2, as carvacrol is, increasing the possibility of agent-specific risk profiles for individual COX inhibitors. Therefore, the authors
themselves state that it seems plausible that the adverse effect profile of COX inhibitors in COVID-19 subjects may differ from drug to drug.

It is important to highlight the preventive effect of carvacrol on the levels of total and differential leukocytes and serum levels of MDA and IL-8, in a COPD model in guinea pigs, comparable to the effect of dexamethasone, a product used in the treatment of patients with COPD. In this study, the researchers evaluated 3 different concentrations of carvacrol in addition to dexamethasone and obtained positive results in all three concentrations (Mahtaj et al. 2015).

According to the study by Ferrara and Vitiello (2021), epidemiological evidence showed the efficacy of dexamethasone in severe COVID-19 in reducing mortality. Can such a finding be extended to the effects of carvacrol, considering that there are already experimental studies with it that resulted in stabilization of the vascular endothelial barrier, as mentioned above? This question is important, since most of the studies cited here are experimental.

Just in 2019, the first clinical trial with 20 patients with non-infectious obstructive pulmonary disease secondary to prolonged exposure to sulfur mustard using carvacrol was published, yielding two publications. This study showed that there was a reduction in inflammatory cells and oxidative biomarkers, in addition to showing improvement in the results of pulmonary strength tests in patients treated with carvacrol (Khazdair and Boskabady 2019a, b).

Anyway, the benefits of carvacrol are numerous and the therapeutic possibilities too. With this description, the question arises: would carvacrol be a supporting treatment option, effective in minimizing the deleterious effects of COVID-19? Helping to control viral duplication, cytokine storm, and oxidative stress? COVID-19 has negatively impacted the lives of thousands of people, whether due to mortality or its economic, mental, and social impacts. There is still a lot to discover and research.

Declarations

Conflict of interest The authors declare no competing interests.

References

Asselah T, Durantel D, Pasmant E et al (2021) COVID-19: Discovery, diagnostics and drug development. J Hepatol 74(1):168–184
Baser K (2008) Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr Pharm Des 14:3106–3119
Beena, Kumar D, Rawat D (2013) Synthesis and antioxidant activity of thymol and carvacrol based Schiff bases. Bioorg Med Chem Lett 23:641–645

Boskabady MH, Gholami ML (2015) Lung inflammation changes and oxidative stress induced by cigarette smoke exposure in guinea pigs affected by Zataria multiflora and its constituent, carvacrol. BMC Complement Altern Med 15:39
Botelho MA, Martins JG, Ruela RS et al (2009) Protective effect of locally applied carvacrol gel on ligature-induced periodontitis in rats: aapping mode AFM study. Phytother Res 23:1439–1448
Code of Federal Regulations Title 21, Food additives permitted for direct addition to food for human consumption; flavoring agents and related substances; synthetic flavoring substances and adjuvants. In 21CFR172.515, U.S. Food and Drug Administration, Ed. revised as of April 1, 2013
Ferrara F, Vitiello A (2021) Efficacy of synthetic glucocorticoids in COVID-19 endothelitis. Naunyn Schmiedeberg’s Arch Pharmacol 394(5):1003–1007

Ghorani V, Alavinezhad A, Rajabi O et al (2018) Safety and tolerability of carvacrol in healthy subjects: a phase I clinical study. Drug Chem Toxicol 44:177–189
Guimarães A, Oliveira G, Melo M et al (2010) Bioassay-guided evaluation of antioxidant and antinociceptive activities of carvacrol. Basic Clin Pharmacol Toxicol 107(6):949–57
Guimarães A, Xavier M, Santana M et al (2012) Carvacrol attenuates mechanical hypernociception and inflammatory response. Naunyn-Schmiedeberg’s Arch Pharmacol 385:253–263
He L, Mo H, Hadisusilo S et al (1997) Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 127:668–674
Hotta M, Nakata R, Katsukawa M et al (2010) Carvacrol, a component of thyme oil, activates PPARG alpha and gamma, and suppresses COX-2 expression. J Lipid Res 51:132–139
Hyldgaard M, Mygind T, Meyer RL (2012) Essential oils in food preservation: mode of action, synergies, and interactions with food matrix components. Front Microbiol 3:12
Ipek E et al (2005) Genotoxicity and antigenotoxicity of Origanum oil and carvacrol evaluated by Ames Salmonella/microsomal test. Food Chem 93:551–556
Khalaf K, Papp N, Chou JTT et al (2020) SARS-CoV-2: pathogenesis, and advancements in diagnostics and treatment. Front Immunol 11:570927
Khazdair MR, Boskabady MH (2019a) A double-blind, randomized, placebo-controlled clinical trial on the effect of carvacrol on serum cytokine levels and pulmonary function tests in sulfur mustard induced lung injury. Cytokine 113:311–318
Khazdair MR, Boskabady MH (2019b) The effect of carvacrol on inflammatory mediators and respiratory symptoms in veterans exposed to sulfur mustard, a randomized, placebo-controlled trial. Respir Med 150:21–29
Khoury M, Stien D, Eparvier V et al (2016) Report on the medicinal use of eleven Lamiaceae species in Lebanon and rationalization of their antimicrobial potential by examination of the chemical composition and antimicrobial activity of their essential oils. Evid Based Complement Alternat Med Ecam 2016:2547169
Lambert RJ, Skandamis PN, Coote PJ et al (2001) A study of the minimal inhibitory concentration and mode of action of oregano essential oil, thymol and carvacrol. J Appl Microbiol 91:453–462
Landa P, Kokoska L, Pribylova M et al (2009) In vitro antiinflammatory activity of carvacrol: inhibitory effect on COX-2 catalyzed prostaglandin E(2) biosynthesis. Arch Pharm Res 32(1):75–78
Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5:562–569
Lima M, Quintans-Júnior L, Santana W et al (2013) Antiinflammatory effects of carvacrol: evidence for a key role of interleukin-10. Eur J Pharmacol 699:112–117

© Springer
Liolios CC, Gortzi O, Lalas S et al (2009) Liposomal incorporation of carvacrol and thymol isolated from the essential oil of Origanum dictamnus L. and in vitro antimicrobial activity. Food Chem. 112:77–83

Mahtaj LG, Feizpour A, Kianmehr M et al (2015) The effect of carvacrol on systemic inflammation in guinea pigs model of COPD induced by cigarette smoke exposure. Pharmacol Rep 67:140–145

Mastelic J, Jerkovic I, Blazevic I et al (2008) Comparative study on the antioxidant and biological activities of carvacrol, thymol, and eugenol derivatives. J Agric Food Chem 56:3989–3996

Mathela CS, Singh KK, Gupta VK (2010) Synthesis and in vitro antibacterial activity of thymol and carvacrol derivatives. Acta Polym Pharm 67:375–380

Pete UD, Zade CM, Bhosale JD et al (2012) Hybrid molecules of carvacrol and benzoyl urea/thiourea with potential applications in agriculture and medicine. Bioorg Med Chem Lett 22:5550–5554

Pina-Vaz C, Rodrigues AG, Pinto E et al (2004) Antifungal activity of Thymus oils and their major compounds. J Eur Acad Dermatol Venereol 18:73–78

Reese JT, Coleman B, Chan L et al (2021) Cyclooxygenase inhibitor use is associated with increased COVID-19 severity. medRxiv 13:21255438

Şen HS, Şen V, Bozkurt M et al (2014) Carvacrol and pomegranate extract in treating methotrexate-induced lung oxidative injury in rats. Med Sci Monit 20:1983–1990

Silva ER, de Carvalho FO, Teixeira LGB et al (2018) Pharmacological effects of carvacrol in in vitro studies: a review. Curr Pharm Des 24(29):3454–3465

Son D-J, Park Y-H, Kim Y-M et al (2005) Antiplatelet activity of Thujaopsis dolabrata var. hondai-derived componente against platelet aggregation. J Microbiol Biotech 15:425–7

Ultee A, Smid EJ (2001) Influence of carvacrol on growth and toxin production by Bacillus Cereus. Int J Food Microbiol 64:373–378

Uyanoglu M, Canbek M, Aral E et al (2008) Effects of carvacrol upon the liver of rats undergoing partial hepatectomy. Phytomedicine 15:226–229

Wagner H, Wierer M, Bauer R (1986) In vitro inhibition of prostaglandin biosynthesis by essential oils and phenolic compounds. Planta Med 52:184–187

Wei Y, Qing L, Sujuan Z (2013) Carvacrol protects against acute myocardial infarction of rats via anti-oxidative and anti-apoptotic pathways. Biol Pharm Bull 36(4):579–584

Zhao Y, Zhao Z, Wang Y et al (2020) Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv

Zhong Z, Wang B, Dai M et al (2013) Carvacrol alleviates cerebral edema by modulating AQP4 expression after intracerebral hemorrhage in mice. Neurosci Lett 25(555):24–29

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.